Free Trial
→ Did You See Trump’s Manhattan Project Bombshell? (From Banyan Hill Publishing) (Ad)

10 Best Penny Stocks to Buy Now - 9 of 10

Slide 9
Back to 8
Continue to 10
 
Back to 8
Continue to 10
 

Nektar Therapeutics (NASDAQ:NKTR)

Number of Upgrades from Top-Ranked Analysts
4 (in the last 90 days)
Consensus Rating
Moderate Buy
Rating Score
2.9
Ratings Breakdown
5 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$4.08 (344.8% Upside)

About Nektar Therapeutics

Nektar Therapeutics logoNektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
1/13/2025HC WainwrightReiterated RatingBuy ➝ Buy$6.50 ➝ $6.50
1/8/2025B. RileyInitiated CoverageBuy$4.00
1/7/2025B. RileyUpgradeStrong-Buy
12/10/2024HC WainwrightInitiated CoverageBuy$6.50
11/4/2024Piper SandlerInitiated CoverageOverweight$7.00
9/30/2024BTIG ResearchReiterated RatingBuy$4.00
6/28/2024Rodman & RenshawInitiated CoverageBuy$2.00
3/6/2024Jefferies Financial GroupBoost Price TargetHold ➝ Hold$0.50 ➝ $1.00
3/5/2024William BlairReiterated RatingMarket Perform
11/20/2023JPMorgan Chase & Co.Reiterated RatingUnderweight
Slide 9
Back to 8
Continue to 10
 

More From MarketBeat
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...
Brownstone Research | Sponsored
20 Stocks to Sell Now
Most people know that Wall Street analyst recommendations are overstated because of pressure from public compa...
MarketBeat
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...
Crypto Swap Profits | Sponsored
7 Dividend Stocks to Buy Under $20
On September 18, 2024, the Federal Reserve dropped its federal funds rate by 50 basis points (0.5%). Furthermo...
MarketBeat
Did You See Trump’s Manhattan Project Bombshell?
This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...
Banyan Hill Publishing | Sponsored
7 Best Data Center Stocks to Own for the Long Haul
Investing is often about timing and basic predictive analysis. That is, you want to have your capital in secto...
MarketBeat